SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'S91'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1FMO_E_ADNE351_1 (CAMP-DEPENDENT PROTEIN KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 GLY A1003 VAL A1010 ALA A1028 VAL A1060 ASN A1137 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 3.9A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None	0.74A	1fmoE-2z8cA: 26.0	1fmoE-2z8cA: 24.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1M17_A_AQ4A999_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	8 / 12	LEU A1002 ALA A1028 LYS A1030 GLU A1047 LEU A1078 MET A1079 GLY A1082 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None S91 A 1 (-4.7A) None S91 A 1 (-3.3A) None	0.82A	1m17A-2z8cA: 31.9	1m17A-2z8cA: 32.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_A_STIA3_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 MET A1051 VAL A1060	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None	0.51A	1opjA-2z8cA: 28.8	1opjA-2z8cA: 38.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	VAL A1010 ALA A1028 GLU A1047 LEU A1123 HIS A1130 GLY A1149	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None None	0.76A	1uwjA-2z8cA: 8.2	1uwjA-2z8cA: 32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	VAL A1010 ALA A1028 GLU A1047 LEU A1123 HIS A1130 GLY A1149	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None None	0.75A	1uwjB-2z8cA: 8.2	1uwjB-2z8cA: 32.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XBB_A_STIA1_1 (TYROSINE-PROTEIN KINASE SYK)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 9	LEU A1002 VAL A1010 ALA A1028 MET A1076 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) S91 A 1 (-3.3A)	0.37A	1xbbA-2z8cA: 31.9	1xbbA-2z8cA: 32.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XKK_A_FMMA91_2 (EPIDERMAL GROWTH FACTOR RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 9	LEU A1002 VAL A1010 LEU A1062 LEU A1078 MET A1079	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) None S91 A 1 (-4.7A) None	0.57A	1xkkA-2z8cA: 22.4	1xkkA-2z8cA: 31.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XKK_A_FMMA91_2 (EPIDERMAL GROWTH FACTOR RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 9	LEU A1002 VAL A1010 LYS A1030 LEU A1062 LEU A1078	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 ( 4.2A) None S91 A 1 (-4.7A)	0.61A	1xkkA-2z8cA: 22.4	1xkkA-2z8cA: 31.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2FUM_D_MIXD3539_1 (PROBABLE SERINE/THREONINE-PRO TEIN KINASE PKNB)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 GLY A1003 GLY A1005 VAL A1010 ALA A1028 MET A1076 ASN A1137	S91 A 1 ( 4.1A) S91 A 1 ( 3.9A) None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) None	0.89A	2fumD-2z8cA: 24.7	2fumD-2z8cA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_B_1N1B502_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 MET A1051 VAL A1060 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None S91 A 1 (-3.3A)	0.47A	2gqgB-2z8cA: 33.0	2gqgB-2z8cA: 40.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_C_STIC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	4 / 6	LEU A1002 VAL A1050 MET A1051 MET A1079	S91 A 1 ( 4.1A) None None None	0.68A	2hyyC-2z8cA: 29.6	2hyyC-2z8cA: 40.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITO_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	LEU A1002 ALA A1028 LYS A1030 GLU A1047 MET A1051 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None S91 A 1 (-3.3A)	0.70A	2itoA-2z8cA: 30.5	2itoA-2z8cA: 32.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITY_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	8 / 12	LEU A1002 GLY A1003 VAL A1010 ALA A1028 GLU A1047 MET A1051 GLY A1082 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 3.9A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None S91 A 1 (-3.3A) None	0.76A	2ityA-2z8cA: 23.5	2ityA-2z8cA: 32.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITZ_A_IREA2021_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	8 / 12	LEU A1002 VAL A1010 ALA A1028 LYS A1030 GLU A1047 MET A1051 GLY A1082 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None S91 A 1 (-3.3A) None	0.78A	2itzA-2z8cA: 23.5	2itzA-2z8cA: 32.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WGJ_A_VGHA2346_1 (HEPATOCYTE GROWTH FACTOR RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	GLY A1003 VAL A1010 ALA A1028 MET A1079 GLY A1082 MET A1139 ASP A1150	S91 A 1 ( 3.9A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-3.3A) S91 A 1 ( 3.7A) None	0.67A	2wgjA-2z8cA: 22.6	2wgjA-2z8cA: 38.05
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2XP2_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 9	LEU A1002 VAL A1010 ALA A1028 MET A1079 GLY A1082 GLY A1149 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-3.3A) None None	0.55A	2xp2A-2z8cA: 10.8	2xp2A-2z8cA: 44.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_A_B49A1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	VAL A1010 ALA A1028 LEU A1078 MET A1079 GLY A1082 ASP A1150	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 (-4.7A) None S91 A 1 (-3.3A) None	0.70A	2y7jA-2z8cA: 26.5	2y7jA-2z8cA: 24.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_B_B49B1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 10	VAL A1010 ALA A1028 LEU A1078 MET A1079 GLY A1082 ASP A1150	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 (-4.7A) None S91 A 1 (-3.3A) None	0.71A	2y7jB-2z8cA: 26.9	2y7jB-2z8cA: 24.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	ALA A1028 LYS A1030 GLU A1047 MET A1051 VAL A1060 MET A1079 GLY A1082	S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None None None S91 A 1 (-3.3A)	0.69A	2zvaA-2z8cA: 31.9	2zvaA-2z8cA: 35.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 ALA A1028 GLU A1047 MET A1051 VAL A1060 MET A1079 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) None None None None S91 A 1 (-3.3A)	0.55A	2zvaA-2z8cA: 31.9	2zvaA-2z8cA: 35.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	8 / 10	ARG A1000 LEU A1002 ALA A1028 LYS A1030 VAL A1060 LEU A1078 MET A1079 GLY A1082	None S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None S91 A 1 (-4.7A) None S91 A 1 (-3.3A)	0.66A	3aoxA-2z8cA: 29.6	3aoxA-2z8cA: 44.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3C7Q_A_XINA1172_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	LEU A1002 GLY A1003 GLU A1012 ALA A1028 LYS A1030 VAL A1060	S91 A 1 ( 4.1A) S91 A 1 ( 3.9A) None S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None	0.61A	3c7qA-2z8cA: 21.6	3c7qA-2z8cA: 36.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	ALA A1028 VAL A1050 MET A1051 GLY A1082 HIS A1130	S91 A 1 (-3.2A) None None S91 A 1 (-3.3A) None	0.57A	3cs9B-2z8cA: 23.4	3cs9B-2z8cA: 40.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	ALA A1028 VAL A1050 MET A1051 GLY A1082 HIS A1130	S91 A 1 (-3.2A) None None S91 A 1 (-3.3A) None	0.53A	3cs9D-2z8cA: 23.3	3cs9D-2z8cA: 40.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EYG_A_MI1A1_1 (TYROSINE-PROTEIN KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	9 / 12	LEU A1002 GLY A1003 GLY A1005 GLY A1008 VAL A1010 ALA A1028 MET A1076 ASN A1137 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 3.9A) None None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) None None	0.86A	3eygA-2z8cA: 31.4	3eygA-2z8cA: 35.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EYG_A_MI1A1_1 (TYROSINE-PROTEIN KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	9 / 12	LEU A1002 GLY A1003 GLY A1005 GLY A1008 VAL A1010 LYS A1030 MET A1076 ASN A1137 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 3.9A) None None S91 A 1 ( 4.9A) S91 A 1 ( 4.2A) S91 A 1 ( 4.9A) None None	1.01A	3eygA-2z8cA: 31.4	3eygA-2z8cA: 35.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3G5D_A_1N1A1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 MET A1051 VAL A1060 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None S91 A 1 (-3.3A)	0.51A	3g5dA-2z8cA: 30.5	3g5dA-2z8cA: 37.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GP0_A_NILA1_2 (MITOGEN-ACTIVATED PROTEIN KINASE 11)	2z8c	INSULIN RECEPTOR (Homo sapiens)	4 / 7	VAL A1059 LEU A1078 MET A1079 ILE A1148	None S91 A 1 (-4.7A) None None	0.69A	3gp0A-2z8cA: 22.3	3gp0A-2z8cA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GVU_A_STIA1001_1 (TYROSINE-PROTEIN KINASE ABL2)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 MET A1051 VAL A1060	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None	0.51A	3gvuA-2z8cA: 23.2	3gvuA-2z8cA: 40.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K54_A_1N1A1_1 (TYROSINE-PROTEIN KINASE BTK)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 ALA A1028 LYS A1030 GLU A1047 MET A1051 VAL A1060 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None None S91 A 1 (-3.3A)	0.66A	3k54A-2z8cA: 29.4	3k54A-2z8cA: 36.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_B_STIB2_2 (TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	4 / 6	LEU A1002 VAL A1050 VAL A1060 MET A1079	S91 A 1 ( 4.1A) None None None	0.77A	3k5vB-2z8cA: 22.4	3k5vB-2z8cA: 38.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	4 / 6	VAL A1010 VAL A1050 VAL A1060 MET A1079	S91 A 1 ( 4.9A) None None None	0.73A	3mssD-2z8cA: 23.4	3mssD-2z8cA: 38.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	ALA A1028 GLU A1047 MET A1051 VAL A1060 GLY A1082 HIS A1130	S91 A 1 (-3.2A) None None None S91 A 1 (-3.3A) None	0.81A	3oxzA-2z8cA: 29.2	3oxzA-2z8cA: 39.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_B_STIB4_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 MET A1051 VAL A1060	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None	0.54A	3pyyB-2z8cA: 28.6	3pyyB-2z8cA: 38.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3QLG_B_1N1B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2z8c	INSULIN RECEPTOR (Homo sapiens)	8 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 MET A1051 VAL A1060 GLY A1082 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None S91 A 1 (-3.3A) None	0.76A	3qlgB-2z8cA: 23.6	3qlgB-2z8cA: 37.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	LEU A1002 VAL A1010 ALA A1028 MET A1051 VAL A1060 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None S91 A 1 (-3.3A)	0.37A	3sxrA-2z8cA: 30.6	3sxrA-2z8cA: 37.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_B_1N1B2_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	LEU A1002 VAL A1010 ALA A1028 MET A1051 VAL A1060 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None S91 A 1 (-3.3A)	0.35A	3sxrB-2z8cA: 30.3	3sxrB-2z8cA: 37.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UG2_A_IREA1_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 VAL A1010 ALA A1028 MET A1076 LEU A1078 MET A1079 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) S91 A 1 (-4.7A) None S91 A 1 (-3.3A)	0.65A	3ug2A-2z8cA: 31.3	3ug2A-2z8cA: 32.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WZD_A_LEVA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-3.3A)	0.52A	3wzdA-2z8cA: 22.4	3wzdA-2z8cA: 36.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WZE_A_BAXA1201_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 GLY A1082 LEU A1123 HIS A1130	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-3.3A) None None	0.70A	3wzeA-2z8cA: 30.4	3wzeA-2z8cA: 36.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZBF_A_VGHA3000_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS)	2z8c	INSULIN RECEPTOR (Homo sapiens)	8 / 12	LEU A1002 ALA A1028 LEU A1078 MET A1079 GLY A1082 ASP A1083 GLY A1149 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 (-4.7A) None S91 A 1 (-3.3A) S91 A 1 (-3.7A) None None	0.52A	3zbfA-2z8cA: 23.8	3zbfA-2z8cA: 47.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AGD_A_B49A2000_1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 11	LEU A1002 ALA A1028 LYS A1030 VAL A1060 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None S91 A 1 (-3.3A)	0.55A	4agdA-2z8cA: 29.4	4agdA-2z8cA: 36.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANQ_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 9	LEU A1002 VAL A1010 ALA A1028 MET A1079 GLY A1082 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-3.3A) None	0.59A	4anqA-2z8cA: 30.2	4anqA-2z8cA: 44.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 9	LEU A1002 VAL A1010 ALA A1028 MET A1076 MET A1079 GLY A1082 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) None S91 A 1 (-3.3A) None	0.67A	4ansA-2z8cA: 30.1	4ansA-2z8cA: 44.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CKI_A_ADNA2022_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 11	LEU A1002 GLY A1003 GLY A1005 VAL A1010 ALA A1028 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 3.9A) None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 (-3.3A)	0.18A	4ckiA-2z8cA: 36.0	4ckiA-2z8cA: 40.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4L9I_A_8PRA601_1 (RHODOPSIN KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 7	VAL A1010 ALA A1028 MET A1076 MET A1079 ASP A1083	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) None S91 A 1 (-3.7A)	0.90A	4l9iA-2z8cA: 20.9	4l9iA-2z8cA: 21.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4L9I_B_8PRB601_1 (RHODOPSIN KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 8	GLY A1005 VAL A1010 ALA A1028 MET A1076 MET A1079	None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) None	0.98A	4l9iB-2z8cA: 20.5	4l9iB-2z8cA: 21.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4L9I_B_8PRB601_1 (RHODOPSIN KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 8	VAL A1010 ALA A1028 MET A1076 MET A1079 ASP A1083	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) None S91 A 1 (-3.7A)	0.94A	4l9iB-2z8cA: 20.5	4l9iB-2z8cA: 21.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4L9I_B_8PRB601_1 (RHODOPSIN KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 8	VAL A1010 LYS A1030 MET A1076 MET A1079 ASP A1083	S91 A 1 ( 4.9A) S91 A 1 ( 4.2A) S91 A 1 ( 4.9A) None S91 A 1 (-3.7A)	1.06A	4l9iB-2z8cA: 20.5	4l9iB-2z8cA: 21.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MKC_A_4MKA1503_1 (ALK TYROSINE KINASE RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	10 / 12	LEU A1002 GLY A1005 VAL A1010 ALA A1028 LYS A1030 LEU A1078 GLY A1082 ASP A1083 SER A1086 ASP A1150	S91 A 1 ( 4.1A) None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) S91 A 1 (-4.7A) S91 A 1 (-3.3A) S91 A 1 (-3.7A) None None	0.76A	4mkcA-2z8cA: 30.8	4mkcA-2z8cA: 37.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MKC_A_4MKA1503_1 (ALK TYROSINE KINASE RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 GLY A1008 VAL A1010 ALA A1028 LYS A1030 LEU A1078 ASP A1150	S91 A 1 ( 4.1A) None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) S91 A 1 (-4.7A) None	1.18A	4mkcA-2z8cA: 30.8	4mkcA-2z8cA: 37.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2z8c	INSULIN RECEPTOR (Homo sapiens)	8 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 MET A1051 VAL A1060 GLY A1082 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None S91 A 1 (-3.3A) None	0.60A	4mxoA-2z8cA: 30.7	4mxoA-2z8cA: 37.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0S_A_ADNA500_1 (AURORA KINASE A)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 11	LEU A1002 GLY A1003 VAL A1010 ALA A1028 LYS A1030 ASN A1137 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 3.9A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None	0.81A	4o0sA-2z8cA: 28.2	4o0sA-2z8cA: 25.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_I_ADNI401_1 (CYCLIN-DEPENDENT KINASE 9)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 9	GLY A1005 VAL A1010 ALA A1028 ASP A1083 ASN A1137 ASP A1150	None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 (-3.7A) None None	0.99A	4ogrI-2z8cA: 17.9	4ogrI-2z8cA: 25.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QRC_A_0LIA802_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	ALA A1028 GLU A1047 MET A1051 LEU A1123 ARG A1131	S91 A 1 (-3.2A) None None None PTR A1163 ( 3.6A)	0.99A	4qrcA-2z8cA: 31.4	4qrcA-2z8cA: 37.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4R7I_A_STIA1001_1 (MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	VAL A1010 ALA A1028 LYS A1030 GLU A1047 MET A1051 GLY A1149	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None None	0.63A	4r7iA-2z8cA: 30.9	4r7iA-2z8cA: 35.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4R7I_A_STIA1001_2 (MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	4 / 5	LEU A1002 VAL A1060 VAL A1074 ARG A1131	S91 A 1 ( 4.1A) None None PTR A1163 ( 3.6A)	0.96A	4r7iA-2z8cA: 30.9	4r7iA-2z8cA: 35.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U0I_A_0LIA1001_1 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 10	LEU A1002 VAL A1010 GLU A1047 VAL A1060 VAL A1074 ILE A1148	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) None None None None	0.83A	4u0iA-2z8cA: 30.0	4u0iA-2z8cA: 35.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_B_0LIB1770_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	ALA A1028 GLU A1047 MET A1051 LEU A1123 HIS A1130	S91 A 1 (-3.2A) None None None None	0.81A	4v01B-2z8cA: 22.8	4v01B-2z8cA: 38.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WBO_C_ANWC601_0 (RHODOPSIN KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 6	ARG A1000 LEU A1002 ALA A1028 MET A1076 MET A1079	None S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) None	0.74A	4wboC-2z8cA: 25.3	4wboC-2z8cA: 20.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WKQ_A_IREA1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 ALA A1028 LYS A1030 GLU A1047 MET A1051 LEU A1078 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None S91 A 1 (-4.7A) S91 A 1 (-3.3A)	0.68A	4wkqA-2z8cA: 32.1	4wkqA-2z8cA: 32.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XEY_A_1N1A601_1 (TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 VAL A1010 ALA A1028 LYS A1030 MET A1051 VAL A1060 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None S91 A 1 (-3.3A)	0.60A	4xeyA-2z8cA: 32.6	4xeyA-2z8cA: 30.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_A_1N1A601_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 ALA A1028 GLU A1047 MET A1051 VAL A1060 MET A1079 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) None None None None S91 A 1 (-3.3A)	0.49A	4xliA-2z8cA: 32.5	4xliA-2z8cA: 40.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	VAL A1010 ALA A1028 LYS A1030 GLY A1149 ASP A1150 PHE A1151	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None None	0.72A	4xv2A-2z8cA: 26.9	4xv2A-2z8cA: 30.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	ALA A1028 LYS A1030 GLY A1149 ASP A1150 PHE A1151	S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None None	0.70A	4xv2B-2z8cA: 27.3	4xv2B-2z8cA: 30.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAA_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 9	LEU A1002 VAL A1010 ALA A1028 MET A1079 GLY A1082 GLY A1149 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-3.3A) None None	0.47A	5aaaA-2z8cA: 30.5	5aaaA-2z8cA: 44.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAB_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 10	LEU A1002 VAL A1010 ALA A1028 MET A1079 GLY A1082 GLY A1149 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-3.3A) None None	0.45A	5aabA-2z8cA: 30.4	5aabA-2z8cA: 44.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAC_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 10	LEU A1002 VAL A1010 ALA A1028 MET A1079 GLY A1082 GLY A1149 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-3.3A) None None	0.59A	5aacA-2z8cA: 30.3	5aacA-2z8cA: 44.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	VAL A1010 ALA A1028 LYS A1030 GLY A1149 PHE A1151	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None	0.62A	5cswA-2z8cA: 26.5	5cswA-2z8cA: 31.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	VAL A1010 ALA A1028 LYS A1030 GLY A1149 PHE A1151	S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None	0.68A	5cswB-2z8cA: 26.5	5cswB-2z8cA: 31.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_A_1N1A501_1 (PROTEIN-TYROSINE KINASE 6)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 VAL A1010 ALA A1028 LYS A1030 LEU A1078 GLY A1082 GLY A1149	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) S91 A 1 (-4.7A) S91 A 1 (-3.3A) None	0.45A	5h2uA-2z8cA: 28.5	5h2uA-2z8cA: 36.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 VAL A1010 ALA A1028 LYS A1030 GLY A1082 GLY A1149 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) S91 A 1 (-3.3A) None None	0.76A	5h2uB-2z8cA: 28.8	5h2uB-2z8cA: 36.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 VAL A1010 ALA A1028 LYS A1030 LEU A1078 GLY A1082 GLY A1149	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) S91 A 1 (-4.7A) S91 A 1 (-3.3A) None	0.49A	5h2uB-2z8cA: 28.8	5h2uB-2z8cA: 36.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	ARG A1000 LEU A1002 ALA A1028 LYS A1030 GLY A1082 GLY A1149	None S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) S91 A 1 (-3.3A) None	0.44A	5h2uC-2z8cA: 28.6	5h2uC-2z8cA: 36.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 VAL A1010 ALA A1028 LYS A1030 LEU A1078 GLY A1082 GLY A1149	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) S91 A 1 (-4.7A) S91 A 1 (-3.3A) None	0.51A	5h2uD-2z8cA: 28.7	5h2uD-2z8cA: 36.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	LEU A1002 VAL A1010 LYS A1030 LEU A1078 GLY A1082 GLY A1149 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 ( 4.2A) S91 A 1 (-4.7A) S91 A 1 (-3.3A) None None	0.74A	5h2uD-2z8cA: 28.7	5h2uD-2z8cA: 36.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	GLY A1005 VAL A1010 ALA A1028 LYS A1030 GLY A1149	None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None	0.73A	5hieA-2z8cA: 26.0	5hieA-2z8cA: 32.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	GLY A1005 VAL A1010 ALA A1028 LYS A1030 GLY A1149	None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None	0.74A	5hieB-2z8cA: 9.6	5hieB-2z8cA: 32.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_C_P06C801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	GLY A1003 GLY A1005 VAL A1010 ALA A1028 LYS A1030 GLY A1149	S91 A 1 ( 3.9A) None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None	0.70A	5hieC-2z8cA: 26.7	5hieC-2z8cA: 32.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	GLY A1005 VAL A1010 ALA A1028 LYS A1030 GLY A1149	None S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None	0.74A	5hieD-2z8cA: 26.2	5hieD-2z8cA: 32.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IZF_E_AZ1E2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 6J9-ZEU-DAR-ACA-DAR- NH2)	2z8c	INSULIN RECEPTOR (Homo sapiens)	4 / 7	GLY A1003 GLY A1005 SER A1006 PHE A1007	S91 A 1 ( 3.9A) None None None	0.57A	5izfA-2z8cA: 25.1	5izfA-2z8cA: 23.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IZJ_F_AZ1F2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAR-DAR-DAR)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 7	GLY A1003 GLY A1005 SER A1006 PHE A1007 GLY A1008	S91 A 1 ( 3.9A) None None None None	0.79A	5izjB-2z8cA: 24.6	5izjB-2z8cA: 23.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_B_ADNB401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 9	GLY A1003 VAL A1010 ALA A1028 MET A1076 MET A1079	S91 A 1 ( 3.9A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) None	0.74A	5lw1B-2z8cA: 22.5	5lw1B-2z8cA: 16.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_E_ADNE401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 10	GLY A1003 VAL A1010 ALA A1028 MET A1076 LEU A1078 MET A1079	S91 A 1 ( 3.9A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) S91 A 1 (-4.7A) None	0.69A	5lw1E-2z8cA: 22.3	5lw1E-2z8cA: 16.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_H_ADNH401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 9	GLY A1003 VAL A1010 ALA A1028 MET A1076 LEU A1078 MET A1079	S91 A 1 ( 3.9A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) S91 A 1 (-4.7A) None	0.62A	5lw1H-2z8cA: 22.6	5lw1H-2z8cA: 16.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	5 / 12	ALA A1028 VAL A1050 MET A1051 VAL A1060 HIS A1130	S91 A 1 (-3.2A) None None None None	0.66A	5mo4A-2z8cA: 21.6	5mo4A-2z8cA: 26.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_2 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	4 / 4	VAL A1060 LEU A1078 ASN A1137 ASP A1150	None S91 A 1 (-4.7A) None None	0.90A	5vcyA-2z8cA: 24.3	5vcyA-2z8cA: 27.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5W5V_A_ANWA701_0 (SERINE/THREONINE-PRO TEIN KINASE TBK1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 9	LEU A1002 ALA A1028 VAL A1060 MET A1076 GLY A1082 MET A1139	S91 A 1 ( 4.1A) S91 A 1 (-3.2A) None S91 A 1 ( 4.9A) S91 A 1 (-3.3A) S91 A 1 ( 3.7A)	0.61A	5w5vA-2z8cA: 11.2	5w5vA-2z8cA: 18.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	ARG A1000 LEU A1002 VAL A1010 ALA A1028 GLU A1047 LEU A1078 GLY A1082	None S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-4.7A) S91 A 1 (-3.3A)	0.77A	5y7zA-2z8cA: 24.8	5y7zA-2z8cA: 15.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	2z8c	INSULIN RECEPTOR (Homo sapiens)	7 / 12	ARG A1000 LEU A1002 VAL A1010 ALA A1028 GLU A1047 LEU A1078 GLY A1082	None S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None S91 A 1 (-4.7A) S91 A 1 (-3.3A)	0.77A	5y7zA-2z8cA: 24.8	5y7zA-2z8cA: 22.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_A_LEVA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 MET A1051 GLY A1082	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None S91 A 1 (-3.3A)	0.69A	5zv2A-2z8cA: 22.6	5zv2A-2z8cA: 13.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_B_LEVB801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	LEU A1002 VAL A1010 ALA A1028 LYS A1030 GLU A1047 MET A1051	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None None	0.67A	5zv2B-2z8cA: 30.5	5zv2B-2z8cA: 13.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_B_STIB602_1 (TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	4 / 6	LEU A1002 VAL A1050 MET A1079 GLY A1082	S91 A 1 ( 4.1A) None None S91 A 1 (-3.3A)	0.71A	6hd4B-2z8cA: 22.2	6hd4B-2z8cA: 13.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD6_B_STIB601_0 (TYROSINE-PROTEIN KINASE ABL1)	2z8c	INSULIN RECEPTOR (Homo sapiens)	6 / 12	LEU A1002 VAL A1010 ALA A1028 GLU A1047 MET A1051 VAL A1060	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) None None None	0.52A	6hd6B-2z8cA: 28.3	6hd6B-2z8cA: 13.94

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1FMO_E_ADNE351_1","CAMP-DEPENDENT PROTEIN KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;GLY A1003;VAL A1010;ALA A1028;VAL A1060;ASN A1137;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 3.9A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None","0.74A","1fmoE-2z8cA:26.0",null],["1M17_A_AQ4A999_1","EPIDERMAL GROWTH FACTOR RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",8,"LEU A1002;ALA A1028;LYS A1030;GLU A1047;LEU A1078;MET A1079;GLY A1082;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;S91 A   1 (-4.7A);None;S91 A   1 (-3.3A);None","0.82A","1m17A-2z8cA:31.9","1fmoE-2z8cA:24.79"],["1OPJ_A_STIA3_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;MET A1051;VAL A1060","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None","0.51A","1opjA-2z8cA:28.8","1m17A-2z8cA:32.29"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"VAL A1010;ALA A1028;GLU A1047;LEU A1123;HIS A1130;GLY A1149","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None;None","0.76A","1uwjA-2z8cA:8.2","1opjA-2z8cA:38.98"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"VAL A1010;ALA A1028;GLU A1047;LEU A1123;HIS A1130;GLY A1149","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None;None","0.75A","1uwjB-2z8cA:8.2","1uwjA-2z8cA:32.17"],["1XBB_A_STIA1_1","TYROSINE-PROTEIN KINASE SYK","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"LEU A1002;VAL A1010;ALA A1028;MET A1076;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);S91 A   1 (-3.3A)","0.37A","1xbbA-2z8cA:31.9","1uwjB-2z8cA:32.17"],["1XKK_A_FMMA91_2","EPIDERMAL GROWTH FACTOR RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"LEU A1002;VAL A1010;LEU A1062;LEU A1078;MET A1079","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);None;S91 A   1 (-4.7A);None","0.57A","1xkkA-2z8cA:22.4","1xbbA-2z8cA:32.69"],["1XKK_A_FMMA91_2","EPIDERMAL GROWTH FACTOR RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"LEU A1002;VAL A1010;LYS A1030;LEU A1062;LEU A1078","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 ( 4.2A);None;S91 A   1 (-4.7A)","0.61A","1xkkA-2z8cA:22.4","1xkkA-2z8cA:31.69"],["2FUM_D_MIXD3539_1","PROBABLE SERINE\/THREONINE-PROTEIN KINASE PKNB","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;GLY A1003;GLY A1005;VAL A1010;ALA A1028;MET A1076;ASN A1137","S91 A   1 ( 4.1A);S91 A   1 ( 3.9A);None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);None","0.89A","2fumD-2z8cA:24.7","1xkkA-2z8cA:31.69"],["2GQG_B_1N1B502_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;MET A1051;VAL A1060;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None;S91 A   1 (-3.3A)","0.47A","2gqgB-2z8cA:33.0","2fumD-2z8cA:25.00"],["2HYY_C_STIC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",4,"LEU A1002;VAL A1050;MET A1051;MET A1079","S91 A   1 ( 4.1A);None;None;None","0.68A","2hyyC-2z8cA:29.6","2gqgB-2z8cA:40.39"],["2ITO_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;ALA A1028;LYS A1030;GLU A1047;MET A1051;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None;S91 A   1 (-3.3A)","0.70A","2itoA-2z8cA:30.5","2hyyC-2z8cA:40.92"],["2ITY_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",8,"LEU A1002;GLY A1003;VAL A1010;ALA A1028;GLU A1047;MET A1051;GLY A1082;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 3.9A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;S91 A   1 (-3.3A);None","0.76A","2ityA-2z8cA:23.5","2itoA-2z8cA:32.07"],["2ITZ_A_IREA2021_1","EPIDERMAL GROWTH FACTOR RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",8,"LEU A1002;VAL A1010;ALA A1028;LYS A1030;GLU A1047;MET A1051;GLY A1082;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None;S91 A   1 (-3.3A);None","0.78A","2itzA-2z8cA:23.5","2ityA-2z8cA:32.36"],["2WGJ_A_VGHA2346_1","HEPATOCYTE GROWTH FACTOR RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"GLY A1003;VAL A1010;ALA A1028;MET A1079;GLY A1082;MET A1139;ASP A1150","S91 A   1 ( 3.9A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-3.3A);S91 A   1 ( 3.7A);None","0.67A","2wgjA-2z8cA:22.6","2itzA-2z8cA:32.36"],["2XP2_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;MET A1079;GLY A1082;GLY A1149;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-3.3A);None;None","0.55A","2xp2A-2z8cA:10.8","2wgjA-2z8cA:38.05"],["2Y7J_A_B49A1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"VAL A1010;ALA A1028;LEU A1078;MET A1079;GLY A1082;ASP A1150","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 (-4.7A);None;S91 A   1 (-3.3A);None","0.70A","2y7jA-2z8cA:26.5","2xp2A-2z8cA:44.41"],["2Y7J_B_B49B1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"VAL A1010;ALA A1028;LEU A1078;MET A1079;GLY A1082;ASP A1150","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 (-4.7A);None;S91 A   1 (-3.3A);None","0.71A","2y7jB-2z8cA:26.9","2y7jA-2z8cA:24.56"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"ALA A1028;LYS A1030;GLU A1047;MET A1051;VAL A1060;MET A1079;GLY A1082","S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None;None;None;S91 A   1 (-3.3A)","0.69A","2zvaA-2z8cA:31.9","2y7jB-2z8cA:24.56"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;ALA A1028;GLU A1047;MET A1051;VAL A1060;MET A1079;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);None;None;None;None;S91 A   1 (-3.3A)","0.55A","2zvaA-2z8cA:31.9","2zvaA-2z8cA:35.53"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",8,"ARG A1000;LEU A1002;ALA A1028;LYS A1030;VAL A1060;LEU A1078;MET A1079;GLY A1082","None;S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;S91 A   1 (-4.7A);None;S91 A   1 (-3.3A)","0.66A","3aoxA-2z8cA:29.6","2zvaA-2z8cA:35.53"],["3C7Q_A_XINA1172_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;GLY A1003;GLU A1012;ALA A1028;LYS A1030;VAL A1060","S91 A   1 ( 4.1A);S91 A   1 ( 3.9A);None;S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None","0.61A","3c7qA-2z8cA:21.6","3aoxA-2z8cA:44.41"],["3CS9_B_NILB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"ALA A1028;VAL A1050;MET A1051;GLY A1082;HIS A1130","S91 A   1 (-3.2A);None;None;S91 A   1 (-3.3A);None","0.57A","3cs9B-2z8cA:23.4","3c7qA-2z8cA:36.47"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"ALA A1028;VAL A1050;MET A1051;GLY A1082;HIS A1130","S91 A   1 (-3.2A);None;None;S91 A   1 (-3.3A);None","0.53A","3cs9D-2z8cA:23.3","3cs9B-2z8cA:40.52"],["3EYG_A_MI1A1_1","TYROSINE-PROTEIN KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",9,"LEU A1002;GLY A1003;GLY A1005;GLY A1008;VAL A1010;ALA A1028;MET A1076;ASN A1137;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 3.9A);None;None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);None;None","0.86A","3eygA-2z8cA:31.4","3cs9D-2z8cA:40.52"],["3EYG_A_MI1A1_1","TYROSINE-PROTEIN KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",9,"LEU A1002;GLY A1003;GLY A1005;GLY A1008;VAL A1010;LYS A1030;MET A1076;ASN A1137;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 3.9A);None;None;S91 A   1 ( 4.9A);S91 A   1 ( 4.2A);S91 A   1 ( 4.9A);None;None","1.01A","3eygA-2z8cA:31.4","3eygA-2z8cA:35.54"],["3G5D_A_1N1A1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;MET A1051;VAL A1060;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None;S91 A   1 (-3.3A)","0.51A","3g5dA-2z8cA:30.5","3eygA-2z8cA:35.54"],["3GP0_A_NILA1_2","MITOGEN-ACTIVATED PROTEIN KINASE 11","2z8c","INSULIN RECEPTOR","Homo sapiens",4,"VAL A1059;LEU A1078;MET A1079;ILE A1148","None;S91 A   1 (-4.7A);None;None","0.69A","3gp0A-2z8cA:22.3","3g5dA-2z8cA:37.99"],["3GVU_A_STIA1001_1","TYROSINE-PROTEIN KINASE ABL2","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;MET A1051;VAL A1060","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None","0.51A","3gvuA-2z8cA:23.2","3gp0A-2z8cA:25.00"],["3K54_A_1N1A1_1","TYROSINE-PROTEIN KINASE BTK","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;ALA A1028;LYS A1030;GLU A1047;MET A1051;VAL A1060;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None;None;S91 A   1 (-3.3A)","0.66A","3k54A-2z8cA:29.4","3gvuA-2z8cA:40.26"],["3K5V_B_STIB2_2","TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",4,"LEU A1002;VAL A1050;VAL A1060;MET A1079","S91 A   1 ( 4.1A);None;None;None","0.77A","3k5vB-2z8cA:22.4","3k54A-2z8cA:36.71"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",4,"VAL A1010;VAL A1050;VAL A1060;MET A1079","S91 A   1 ( 4.9A);None;None;None","0.73A","3mssD-2z8cA:23.4","3k5vB-2z8cA:38.98"],["3OXZ_A_0LIA1_1","TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"ALA A1028;GLU A1047;MET A1051;VAL A1060;GLY A1082;HIS A1130","S91 A   1 (-3.2A);None;None;None;S91 A   1 (-3.3A);None","0.81A","3oxzA-2z8cA:29.2","3mssD-2z8cA:38.98"],["3PYY_B_STIB4_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;MET A1051;VAL A1060","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None","0.54A","3pyyB-2z8cA:28.6","3oxzA-2z8cA:39.74"],["3QLG_B_1N1B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","2z8c","INSULIN RECEPTOR","Homo sapiens",8,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;MET A1051;VAL A1060;GLY A1082;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None;S91 A   1 (-3.3A);None","0.76A","3qlgB-2z8cA:23.6","3pyyB-2z8cA:38.84"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;VAL A1010;ALA A1028;MET A1051;VAL A1060;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;S91 A   1 (-3.3A)","0.37A","3sxrA-2z8cA:30.6","3qlgB-2z8cA:37.99"],["3SXR_B_1N1B2_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;VAL A1010;ALA A1028;MET A1051;VAL A1060;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;S91 A   1 (-3.3A)","0.35A","3sxrB-2z8cA:30.3","3sxrA-2z8cA:37.83"],["3UG2_A_IREA1_1","EPIDERMAL GROWTH FACTOR RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;MET A1076;LEU A1078;MET A1079;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);S91 A   1 (-4.7A);None;S91 A   1 (-3.3A)","0.65A","3ug2A-2z8cA:31.3","3sxrB-2z8cA:37.83"],["3WZD_A_LEVA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-3.3A)","0.52A","3wzdA-2z8cA:22.4","3ug2A-2z8cA:32.18"],["3WZE_A_BAXA1201_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;GLY A1082;LEU A1123;HIS A1130","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-3.3A);None;None","0.70A","3wzeA-2z8cA:30.4","3wzdA-2z8cA:36.79"],["3ZBF_A_VGHA3000_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","2z8c","INSULIN RECEPTOR","Homo sapiens",8,"LEU A1002;ALA A1028;LEU A1078;MET A1079;GLY A1082;ASP A1083;GLY A1149;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 (-4.7A);None;S91 A   1 (-3.3A);S91 A   1 (-3.7A);None;None","0.52A","3zbfA-2z8cA:23.8","3wzeA-2z8cA:36.79"],["4AGD_A_B49A2000_1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"LEU A1002;ALA A1028;LYS A1030;VAL A1060;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;S91 A   1 (-3.3A)","0.55A","4agdA-2z8cA:29.4","3zbfA-2z8cA:47.40"],["4ANQ_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;VAL A1010;ALA A1028;MET A1079;GLY A1082;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-3.3A);None","0.59A","4anqA-2z8cA:30.2","4agdA-2z8cA:36.47"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;MET A1076;MET A1079;GLY A1082;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);None;S91 A   1 (-3.3A);None","0.67A","4ansA-2z8cA:30.1","4anqA-2z8cA:44.10"],["4CKI_A_ADNA2022_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;GLY A1003;GLY A1005;VAL A1010;ALA A1028;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 3.9A);None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 (-3.3A)","0.18A","4ckiA-2z8cA:36.0","4ansA-2z8cA:44.41"],["4L9I_A_8PRA601_1","RHODOPSIN KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"VAL A1010;ALA A1028;MET A1076;MET A1079;ASP A1083","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);None;S91 A   1 (-3.7A)","0.90A","4l9iA-2z8cA:20.9","4ckiA-2z8cA:40.25"],["4L9I_B_8PRB601_1","RHODOPSIN KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"GLY A1005;VAL A1010;ALA A1028;MET A1076;MET A1079","None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);None","0.98A","4l9iB-2z8cA:20.5","4l9iA-2z8cA:21.46"],["4L9I_B_8PRB601_1","RHODOPSIN KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"VAL A1010;ALA A1028;MET A1076;MET A1079;ASP A1083","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);None;S91 A   1 (-3.7A)","0.94A","4l9iB-2z8cA:20.5","4l9iB-2z8cA:21.46"],["4L9I_B_8PRB601_1","RHODOPSIN KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"VAL A1010;LYS A1030;MET A1076;MET A1079;ASP A1083","S91 A   1 ( 4.9A);S91 A   1 ( 4.2A);S91 A   1 ( 4.9A);None;S91 A   1 (-3.7A)","1.06A","4l9iB-2z8cA:20.5","4l9iB-2z8cA:21.46"],["4MKC_A_4MKA1503_1","ALK TYROSINE KINASE RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",10,"LEU A1002;GLY A1005;VAL A1010;ALA A1028;LYS A1030;LEU A1078;GLY A1082;ASP A1083;SER A1086;ASP A1150","S91 A   1 ( 4.1A);None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);S91 A   1 (-4.7A);S91 A   1 (-3.3A);S91 A   1 (-3.7A);None;None","0.76A","4mkcA-2z8cA:30.8","4l9iB-2z8cA:21.46"],["4MKC_A_4MKA1503_1","ALK TYROSINE KINASE RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;GLY A1008;VAL A1010;ALA A1028;LYS A1030;LEU A1078;ASP A1150","S91 A   1 ( 4.1A);None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);S91 A   1 (-4.7A);None","1.18A","4mkcA-2z8cA:30.8","4mkcA-2z8cA:37.99"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","2z8c","INSULIN RECEPTOR","Homo sapiens",8,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;MET A1051;VAL A1060;GLY A1082;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None;S91 A   1 (-3.3A);None","0.60A","4mxoA-2z8cA:30.7","4mkcA-2z8cA:37.99"],["4O0S_A_ADNA500_1","AURORA KINASE A","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;GLY A1003;VAL A1010;ALA A1028;LYS A1030;ASN A1137;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 3.9A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None","0.81A","4o0sA-2z8cA:28.2","4mxoA-2z8cA:37.99"],["4OGR_I_ADNI401_1","CYCLIN-DEPENDENT KINASE 9","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"GLY A1005;VAL A1010;ALA A1028;ASP A1083;ASN A1137;ASP A1150","None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 (-3.7A);None;None","0.99A","4ogrI-2z8cA:17.9","4o0sA-2z8cA:25.08"],["4QRC_A_0LIA802_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"ALA A1028;GLU A1047;MET A1051;LEU A1123;ARG A1131","S91 A   1 (-3.2A);None;None;None;PTR A1163 ( 3.6A)","0.99A","4qrcA-2z8cA:31.4","4ogrI-2z8cA:25.07"],["4R7I_A_STIA1001_1","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"VAL A1010;ALA A1028;LYS A1030;GLU A1047;MET A1051;GLY A1149","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None;None","0.63A","4r7iA-2z8cA:30.9","4qrcA-2z8cA:37.08"],["4R7I_A_STIA1001_2","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",4,"LEU A1002;VAL A1060;VAL A1074;ARG A1131","S91 A   1 ( 4.1A);None;None;PTR A1163 ( 3.6A)","0.96A","4r7iA-2z8cA:30.9","4r7iA-2z8cA:35.74"],["4U0I_A_0LIA1001_1","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;VAL A1010;GLU A1047;VAL A1060;VAL A1074;ILE A1148","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);None;None;None;None","0.83A","4u0iA-2z8cA:30.0","4r7iA-2z8cA:35.74"],["4V01_B_0LIB1770_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"ALA A1028;GLU A1047;MET A1051;LEU A1123;HIS A1130","S91 A   1 (-3.2A);None;None;None;None","0.81A","4v01B-2z8cA:22.8","4u0iA-2z8cA:35.19"],["4WBO_C_ANWC601_0","RHODOPSIN KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"ARG A1000;LEU A1002;ALA A1028;MET A1076;MET A1079","None;S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);None","0.74A","4wboC-2z8cA:25.3","4v01B-2z8cA:38.78"],["4WKQ_A_IREA1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;ALA A1028;LYS A1030;GLU A1047;MET A1051;LEU A1078;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None;S91 A   1 (-4.7A);S91 A   1 (-3.3A)","0.68A","4wkqA-2z8cA:32.1","4wboC-2z8cA:20.60"],["4XEY_A_1N1A601_1","TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;LYS A1030;MET A1051;VAL A1060;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None;S91 A   1 (-3.3A)","0.60A","4xeyA-2z8cA:32.6","4wkqA-2z8cA:32.27"],["4XLI_A_1N1A601_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;ALA A1028;GLU A1047;MET A1051;VAL A1060;MET A1079;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);None;None;None;None;S91 A   1 (-3.3A)","0.49A","4xliA-2z8cA:32.5","4xeyA-2z8cA:30.14"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"VAL A1010;ALA A1028;LYS A1030;GLY A1149;ASP A1150;PHE A1151","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None;None","0.72A","4xv2A-2z8cA:26.9","4xliA-2z8cA:40.74"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"ALA A1028;LYS A1030;GLY A1149;ASP A1150;PHE A1151","S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None;None","0.70A","4xv2B-2z8cA:27.3","4xv2A-2z8cA:30.54"],["5AAA_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;MET A1079;GLY A1082;GLY A1149;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-3.3A);None;None","0.47A","5aaaA-2z8cA:30.5","4xv2B-2z8cA:30.54"],["5AAB_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;MET A1079;GLY A1082;GLY A1149;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-3.3A);None;None","0.45A","5aabA-2z8cA:30.4","5aaaA-2z8cA:44.10"],["5AAC_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;MET A1079;GLY A1082;GLY A1149;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-3.3A);None;None","0.59A","5aacA-2z8cA:30.3","5aabA-2z8cA:44.10"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"VAL A1010;ALA A1028;LYS A1030;GLY A1149;PHE A1151","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None","0.62A","5cswA-2z8cA:26.5","5aacA-2z8cA:44.41"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"VAL A1010;ALA A1028;LYS A1030;GLY A1149;PHE A1151","S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None","0.68A","5cswB-2z8cA:26.5","5cswA-2z8cA:31.17"],["5H2U_A_1N1A501_1","PROTEIN-TYROSINE KINASE 6","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;LYS A1030;LEU A1078;GLY A1082;GLY A1149","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);S91 A   1 (-4.7A);S91 A   1 (-3.3A);None","0.45A","5h2uA-2z8cA:28.5","5cswB-2z8cA:31.17"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;LYS A1030;GLY A1082;GLY A1149;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);S91 A   1 (-3.3A);None;None","0.76A","5h2uB-2z8cA:28.8","5h2uA-2z8cA:36.30"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;LYS A1030;LEU A1078;GLY A1082;GLY A1149","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);S91 A   1 (-4.7A);S91 A   1 (-3.3A);None","0.49A","5h2uB-2z8cA:28.8","5h2uB-2z8cA:36.30"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"ARG A1000;LEU A1002;ALA A1028;LYS A1030;GLY A1082;GLY A1149","None;S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);S91 A   1 (-3.3A);None","0.44A","5h2uC-2z8cA:28.6","5h2uB-2z8cA:36.30"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;ALA A1028;LYS A1030;LEU A1078;GLY A1082;GLY A1149","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);S91 A   1 (-4.7A);S91 A   1 (-3.3A);None","0.51A","5h2uD-2z8cA:28.7","5h2uC-2z8cA:36.30"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"LEU A1002;VAL A1010;LYS A1030;LEU A1078;GLY A1082;GLY A1149;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 ( 4.2A);S91 A   1 (-4.7A);S91 A   1 (-3.3A);None;None","0.74A","5h2uD-2z8cA:28.7","5h2uD-2z8cA:36.30"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"GLY A1005;VAL A1010;ALA A1028;LYS A1030;GLY A1149","None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None","0.73A","5hieA-2z8cA:26.0","5h2uD-2z8cA:36.30"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"GLY A1005;VAL A1010;ALA A1028;LYS A1030;GLY A1149","None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None","0.74A","5hieB-2z8cA:9.6","5hieA-2z8cA:32.38"],["5HIE_C_P06C801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"GLY A1003;GLY A1005;VAL A1010;ALA A1028;LYS A1030;GLY A1149","S91 A   1 ( 3.9A);None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None","0.70A","5hieC-2z8cA:26.7","5hieB-2z8cA:32.38"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"GLY A1005;VAL A1010;ALA A1028;LYS A1030;GLY A1149","None;S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None","0.74A","5hieD-2z8cA:26.2","5hieC-2z8cA:32.38"],["5IZF_E_AZ1E2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;6J9-ZEU-DAR-ACA-DAR-NH2","2z8c","INSULIN RECEPTOR","Homo sapiens",4,"GLY A1003;GLY A1005;SER A1006;PHE A1007","S91 A   1 ( 3.9A);None;None;None","0.57A","5izfA-2z8cA:25.1","5hieD-2z8cA:32.38"],["5IZJ_F_AZ1F2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAR-DAR-DAR","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"GLY A1003;GLY A1005;SER A1006;PHE A1007;GLY A1008","S91 A   1 ( 3.9A);None;None;None;None","0.79A","5izjB-2z8cA:24.6","5izfA-2z8cA:23.39"],["5LW1_B_ADNB401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"GLY A1003;VAL A1010;ALA A1028;MET A1076;MET A1079","S91 A   1 ( 3.9A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);None","0.74A","5lw1B-2z8cA:22.5","5izjB-2z8cA:23.39"],["5LW1_E_ADNE401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"GLY A1003;VAL A1010;ALA A1028;MET A1076;LEU A1078;MET A1079","S91 A   1 ( 3.9A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);S91 A   1 (-4.7A);None","0.69A","5lw1E-2z8cA:22.3","5lw1B-2z8cA:16.81"],["5LW1_H_ADNH401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"GLY A1003;VAL A1010;ALA A1028;MET A1076;LEU A1078;MET A1079","S91 A   1 ( 3.9A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);S91 A   1 (-4.7A);None","0.62A","5lw1H-2z8cA:22.6","5lw1E-2z8cA:16.81"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",5,"ALA A1028;VAL A1050;MET A1051;VAL A1060;HIS A1130","S91 A   1 (-3.2A);None;None;None;None","0.66A","5mo4A-2z8cA:21.6","5lw1H-2z8cA:16.81"],["5VCY_A_DB8A401_2","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",4,"VAL A1060;LEU A1078;ASN A1137;ASP A1150","None;S91 A   1 (-4.7A);None;None","0.90A","5vcyA-2z8cA:24.3","5mo4A-2z8cA:26.53"],["5W5V_A_ANWA701_0","SERINE\/THREONINE-PROTEIN KINASE TBK1","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;ALA A1028;VAL A1060;MET A1076;GLY A1082;MET A1139","S91 A   1 ( 4.1A);S91 A   1 (-3.2A);None;S91 A   1 ( 4.9A);S91 A   1 (-3.3A);S91 A   1 ( 3.7A)","0.61A","5w5vA-2z8cA:11.2","5vcyA-2z8cA:27.49"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"ARG A1000;LEU A1002;VAL A1010;ALA A1028;GLU A1047;LEU A1078;GLY A1082","None;S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-4.7A);S91 A   1 (-3.3A)","0.77A","5y7zA-2z8cA:24.8","5w5vA-2z8cA:18.76"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","2z8c","INSULIN RECEPTOR","Homo sapiens",7,"ARG A1000;LEU A1002;VAL A1010;ALA A1028;GLU A1047;LEU A1078;GLY A1082","None;S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;S91 A   1 (-4.7A);S91 A   1 (-3.3A)","0.77A","5y7zA-2z8cA:24.8","5y7zA-2z8cA:15.44"],["5ZV2_A_LEVA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;MET A1051;GLY A1082","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;S91 A   1 (-3.3A)","0.69A","5zv2A-2z8cA:22.6","5y7zA-2z8cA:22.84"],["5ZV2_B_LEVB801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;VAL A1010;ALA A1028;LYS A1030;GLU A1047;MET A1051","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;None","0.67A","5zv2B-2z8cA:30.5","5zv2A-2z8cA:13.68"],["6HD4_B_STIB602_1","TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",4,"LEU A1002;VAL A1050;MET A1079;GLY A1082","S91 A   1 ( 4.1A);None;None;S91 A   1 (-3.3A)","0.71A","6hd4B-2z8cA:22.2","5zv2B-2z8cA:13.68"],["6HD6_B_STIB601_0","TYROSINE-PROTEIN KINASE ABL1","2z8c","INSULIN RECEPTOR","Homo sapiens",6,"LEU A1002;VAL A1010;ALA A1028;GLU A1047;MET A1051;VAL A1060","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);None;None;None","0.52A","6hd6B-2z8cA:28.3","6hd4B-2z8cA:13.94"]]